3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
130
Recurrence
34
Lymphoma, Follicular
28
Lymphoma, Large B-Cell, Diffuse
27
Lymphoma, Non-Hodgkin
23
Neoplasms
13
Lymphoma
13
Lymphoma, Mantle-Cell
11
Lymphoma, B-Cell, Marginal Zone
11
Leukemia, Lymphocytic, Chronic, B-Cell
11
Hematologic Diseases
5
Neoplasms, Plasma Cell
4
Myelodysplastic Syndromes
4
Lymphoma, B-Cell
4
Hematologic Neoplasms
4
Neoplasm Metastasis
3
Melanoma
3
Leukemia, Myeloid, Acute
3
Pyloric Stenosis, Hypertrophic
2
Prostatic Neoplasms
2
Paraproteinemias
2
Ovarian Neoplasms
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell, Peripheral
2
Leukemia-Lymphoma, Adult T-Cell
2
Leukemia, B-Cell
2
Leukemia
2
Immunoproliferative Disorders
2
Hodgkin Disease
2
Carcinoma, Non-Small-Cell Lung
2
Interventions
ibrutinib
3
Rituximab
3
Cyclophosphamide
3
Bortezomib
3
tetulomab tetraxetan lu-177
2
ponatinib
2
fludarabine
2
cobomarsen
2
Vorinostat
2
Lutetium
2
enzalutamide
1
durvalumab
1
cirmtuzumab
1
acalabrutinib
1
Vincristine
1
Prednisone
1
Lutetium-177
1
Lenalidomide
1
KW-2478
1
Imatinib Mesylate
1
Ifosfamide
1
Hsp90 inhibitor KU757
1
Etoposide
1
Doxorubicin
1
Carboplatin
1
CA-4948
1
Brentuximab Vedotin
1
Bendamustine Hydrochloride
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Immune System Diseases
×
Lenalidomide
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts